Literature DB >> 28796995

Heterogeneity of Outcomes in D'Amico Intermediate-Risk Prostate Cancer Patients after Radical Prostatectomy: Influence of Primary and Secondary Gleason Score.

Matthew E Pollard, Adele R Hobbs, Young Suk Kwon, Maria Katsigeorgis, Hugh J Lavery, Adam Levinson, Adrien N Bernstein, Shemille A Collingwood, Simon J Hall, Seyed Behzad Jazayeri, David B Samadi.   

Abstract

AIM: The aim of this study was to clarify and examine the outcomes of prostate cancer patients classified as intermediate risk (IR) using the D'Amico risk classification system, specifically focusing on the influence of primary and secondary biopsy Gleason score (BGS). PATIENTS AND METHODS: An institutional review board-approved database of robotic-assisted radical prostatectomies performed after 2006 was stratified by standard D'Amico criteria. IR patients were then sub-stratified by BGS. Pathologic and intermediate-term biochemical disease-free survival (BDFS) outcomes were analyzed.
RESULTS: Overall, 1,090 patients were classified as D'Amico low-risk, 896 as IR, and 240 as high-risk. Of the 896 IR patients, 63 had BGS 6, 630 were 3 + 4 = 7, and 203 4 + 3 = 7. Among IR patients, as the BGS increased, there was an increasing likelihood of extracapsular extension (21, 28, and 38%, respectively; p = 0.005), positive surgical margins (14, 26, 31%; p = 0.048), and worse 3-year BDFS (96, 94, 88%; p = 0.01). Multivariable logistic regression and Cox regression analyses confirmed differences among IR groups.
CONCLUSION: D'Amico IR patients demonstrate significant heterogeneity in both pathologic outcomes and BDFS. IR patients with a BGS of 6 appear to have similar intermediate-term BDFS as low-risk patients. An increasing BGS from 3 + 3 to 3 + 4 to 4 + 3 results in a higher likelihood of locally-advanced disease and intermediate-term biochemical failure.
© 2017 S. Karger GmbH, Freiburg.

Entities:  

Keywords:  D’Amico; Gleason score; Prostate cancer; Robotic surgery

Mesh:

Substances:

Year:  2017        PMID: 28796995     DOI: 10.1159/000477545

Source DB:  PubMed          Journal:  Oncol Res Treat        ISSN: 2296-5270            Impact factor:   2.825


  1 in total

1.  A Novel Risk Score (P-score) Based on a Three-Gene Signature, for Estimating the Risk of Prostate Cancer-Specific Mortality.

Authors:  Fabian Söderdahl; Li-Di Xu; Johan Bring; Michael Häggman
Journal:  Res Rep Urol       Date:  2022-05-11
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.